<?xml version='1.0'?><!DOCTYPE Annotation PUBLIC "//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN_Modified" "../ModifiedGENIAtypes/Modified_GENIA_event_20.dtd"><Annotation annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=9261367" created="02/06/2006" creator="Noriko Katsu"><PubmedArticleSet><PubmedArticle><MedlineCitation>
<PMID>9261367</PMID>
<Article>
<ArticleTitle>
<sentence id="S1">Inhibition of <term id="T1" lex="human_immunodeficiency_virus_type_1" sem="Virus">human immunodeficiency virus type 1</term> replication in vitro by a novel combination of <term id="T2" lex="anti-Tat_single-chain_intrabodies" sem="Protein_molecule">anti-Tat single-chain intrabodies</term> and <term id="T3" lex="NF-kappa_B_antagonist" sem="Organic_compound_other">NF-kappa B antagonists</term>.</sentence>
<event KT="Investigation" id="E1">
<type class="Negative_regulation"/>
<theme idref="E2"/>
<cause idref="T2"/>
<cause idref="T3"/>
<clue><clueType>Inhibition</clueType> <linkTheme>of</linkTheme> human immunodeficiency virus type 1 replication in vitro <linkCause>by</linkCause> a novel <linkCause>combination of</linkCause> anti-Tat single-chain intrabodies and NF-kappa B antagonists.</clue>
</event>
<event KT="Other" id="E2">
<type class="Viral_life_cycle"/>
<theme idref="T1"/>
<clue>Inhibition of human immunodeficiency virus type 1 <clueType>replication</clueType> in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-kappa B antagonists.</clue>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2"><term id="T4" lex="human_immunodeficiency_virus_type_1_(HIV-1)_Tat" sem="Protein_molecule"><term id="T5" lex="human_immunodeficiency_virus_type_1" sem="Virus">Human immunodeficiency virus type 1</term> (HIV-1) <term id="A1" sem="Protein_molecule">Tat</term></term>, an early <term id="T6" lex="regulatory_protein" sem="Protein_family_or_group">regulatory protein</term> that is critical for <term id="T7" sem="Other"><term id="A14" sem="DNA_domain_or_region"><term id="A2" sem="Virus">viral</term> gene</term> expression</term> and <term id="T12" sem="Other">replication</term>, transactivates the <term id="T8" lex="HIV-1_long_terminal_repeat" sem="DNA_domain_or_region">HIV-1 long terminal repeat</term> (<term id="T9" lex="LTR" sem="DNA_domain_or_region">LTR</term>) via its binding to the <term id="T10" lex="transactivation_response_element" sem="DNA_domain_or_region">transactivation response element</term> (<term id="T11" lex="TAR" sem="DNA_domain_or_region">TAR</term>) and, along with <term id="A8" sem="Protein_family_or_group">other cellular factors</term>, increases <term id="A5" sem="Other">viral transcription</term> <frag id="F5"><term id="A6" sem="Other">initiation</term></frag> and <frag id="F6"><term id="A7" sem="Other">elongation</term></frag>.</sentence>
<event KT="Fact" id="E3">
<type class="Positive_regulation"/>
<theme idref="E43"/>
<cause idref="A1"/>
<clue>Human immunodeficiency virus type 1 (HIV-1) Tat, an early regulatory protein that is <clueType>critical</clueType> <linkTheme>for</linkTheme> viral gene expression and replication, transactivates the HIV-1 long terminal repeat (LTR) via its binding to the transactivation response element (TAR) and, along with other cellular factors, increases viral transcription initiation and elongation.</clue>
</event>
<event KT="Fact" id="E4">
<type class="Positive_regulation"/>
<theme idref="E44"/>
<cause idref="A1"/>
<clue>Human immunodeficiency virus type 1 (HIV-1) Tat, an early regulatory protein that is <clueType>critical</clueType> <linkTheme>for</linkTheme> viral gene expression and replication, transactivates the HIV-1 long terminal repeat (LTR) via its binding to the transactivation response element (TAR) and, along with other cellular factors, increases viral transcription initiation and elongation.</clue>
</event>
<event KT="Other" id="E43">
<type class="Gene_expression"/>
<theme idref="A14"/>
<clue>Human immunodeficiency virus type 1 (HIV-1) Tat, an early regulatory protein that is critical for viral gene <clueType>expression</clueType> and replication, transactivates the HIV-1 long terminal repeat (LTR) via its binding to the transactivation response element (TAR) and, along with other cellular factors, increases viral transcription initiation and elongation.</clue>
</event>
<event KT="Other" id="E44">
<type class="Viral_life_cycle"/>
<theme idref="A2"/>
<clue>Human immunodeficiency virus type 1 (HIV-1) Tat, an early regulatory protein that is critical for viral gene expression and <clueType>replication</clueType>, transactivates the HIV-1 long terminal repeat (LTR) via its binding to the transactivation response element (TAR) and, along with other cellular factors, increases viral transcription initiation and elongation.</clue>
</event>
<event KT="Fact" id="E5">
<type class="Positive_regulation"/>
<theme idref="T9"/>
<cause idref="E6"/>
<clue>Human immunodeficiency virus type 1 (HIV-1) Tat, an early regulatory protein that is critical for viral gene expression and replication, <clueType>transactivates</clueType> the HIV-1 long terminal repeat (LTR) <linkCause>via</linkCause> its binding to the transactivation response element (TAR) and, along with other cellular factors, increases viral transcription initiation and elongation.</clue>
</event>
<event KT="Other" id="E6">
<type class="Binding"/>
<theme idref="A1"/>
<theme idref="T11"/>
<clue>Human immunodeficiency virus type 1 (HIV-1) Tat, an early regulatory protein that is critical for viral gene expression and replication, transactivates the HIV-1 long terminal repeat (LTR) via <corefTheme>its</corefTheme> <clueType>binding</clueType> <linkTheme>to</linkTheme> the transactivation response element (TAR) and, along with other cellular factors, increases viral transcription initiation and elongation.</clue>
</event>
<event KT="Other" id="E7">
<type class="Positive_regulation"/>
<theme idref="A5" idref1="A6"/>
<cause idref="A1"/>
<clue>Human immunodeficiency virus type 1 (HIV-1) Tat, an early regulatory protein that is critical for viral gene expression and replication, transactivates the HIV-1 long terminal repeat (LTR) via its binding to the transactivation response element (TAR) and, along with other cellular factors, <clueType>increases</clueType> viral transcription initiation and elongation.</clue>
</event>
<event KT="Other" id="E8">
<type class="Positive_regulation"/>
<theme idref="A5" idref1="A7"/>
<cause idref="A1"/>
<clue>Human immunodeficiency virus type 1 (HIV-1) Tat, an early regulatory protein that is critical for viral gene expression and replication, transactivates the HIV-1 long terminal repeat (LTR) via its binding to the transactivation response element (TAR) and, along with other cellular factors, <clueType>increases</clueType> viral transcription initiation and elongation.</clue>
</event>
<event KT="Other" id="E9">
<type class="Positive_regulation"/>
<theme idref="A5" idref1="A6"/>
<cause idref="A8"/>
<clue>Human immunodeficiency virus type 1 (HIV-1) Tat, an early regulatory protein that is critical for viral gene expression and replication, transactivates the HIV-1 long terminal repeat (LTR) via its binding to the transactivation response element (TAR) and, along with other cellular factors, <clueType>increases</clueType> viral transcription initiation and elongation.</clue>
</event>
<event KT="Other" id="E10">
<type class="Positive_regulation"/>
<theme idref="A5" idref1="A7"/>
<cause idref="A8"/>
<clue>Human immunodeficiency virus type 1 (HIV-1) Tat, an early regulatory protein that is critical for viral gene expression and replication, transactivates the HIV-1 long terminal repeat (LTR) via its binding to the transactivation response element (TAR) and, along with other cellular factors, <clueType>increases</clueType> viral transcription initiation and elongation.</clue>
</event>
<event KT="Fact" id="E11">
<type class="Correlation"/>
<theme idref="E7"/>
<theme idref="E9"/>
<clue>Human immunodeficiency virus type 1 (HIV-1) Tat, an early regulatory protein that is critical for viral gene expression and replication, transactivates the HIV-1 long terminal repeat (LTR) via its binding to the transactivation response element (TAR) and, <linkTheme>along with</linkTheme> other cellular factors, increases viral transcription initiation and elongation.</clue>
<comment>NO CLUETYPE</comment></event>
<event KT="Fact" id="E40">
<type class="Correlation"/>
<theme idref="E8"/>
<theme idref="E10"/>
<clue>Human immunodeficiency virus type 1 (HIV-1) Tat, an early regulatory protein that is critical for viral gene expression and replication, transactivates the HIV-1 long terminal repeat (LTR) via its binding to the transactivation response element (TAR) and, <linkTheme>along with</linkTheme> other cellular factors, increases viral transcription initiation and elongation.</clue>
<comment>NO CLUETYPE</comment></event>
<sentence id="S3"><term id="A9" sem="Protein_molecule">Tat</term> also superactivates the <term id="T13" lex="HIV-1_promoter" sem="DNA_domain_or_region"><term id="T14" lex="HIV-1" sem="Virus">HIV-1</term> promoter</term> through a <term id="T16" lex="TAR" sem="DNA_domain_or_region">TAR</term>-independent <term id="T15" sem="Other">mechanism</term>, including <cons id="T17" lex="(AND tumor_necrosis_factor_alpha-induced_activation protein_kinase_C_(PKC)-dependent_activation)" sem="(AND Other Other)"><frag id="F7"><term id="A10" sem="Protein_molecule">tumor necrosis factor alpha</term>-induced</frag> and <frag id="F8">protein kinase C (<term id="T18" lex="PKC" sem="Protein_molecule">PKC</term>)-dependent</frag> <frag id="F9">activation</frag></cons> of <term id="T19" lex="NF-kappa_B" sem="Protein_complex">NF-kappa B</term>, and <term id="A11" sem="Organic_compound_other">inhibitors</term> of <term id="T20" lex="Tat" sem="Protein_molecule">Tat</term> and <term id="T21" lex="NF-kappa_B" sem="Protein_complex">NF-kappa B</term> cooperatively down-regulate this <term id="T23" lex="Tat" sem="Protein_molecule">Tat</term>-mediated <term id="T22" sem="Other"><term id="T24" lex="LTR" sem="DNA_domain_or_region">LTR</term> superactivation</term>.</sentence>
<event KT="Other" id="E12">
<type class="Positive_regulation"/>
<theme idref="T13"/>
<cause idref="A9"/>
<clue>Tat also <clueType>superactivates</clueType> the HIV-1 promoter through a TAR-independent mechanism, including tumor necrosis factor alpha-induced and protein kinase C (PKC)-dependent activation of NF-kappa B, and inhibitors of Tat and NF-kappa B cooperatively down-regulate this Tat-mediated LTR superactivation.</clue>
</event>
<event KT="Fact" id="E13">
<type class="Positive_regulation"/>
<theme idref="E12"/>
<cause idref="E16"/>
<clue>Tat also superactivates the HIV-1 promoter <linkCause>through</linkCause> a <corefCause>TAR-independent mechanism</corefCause>, including tumor necrosis factor alpha-induced and protein kinase C (PKC)-dependent activation of NF-kappa B, and inhibitors of Tat and NF-kappa B cooperatively down-regulate this Tat-mediated LTR superactivation.</clue>
<comment>NO CLUETYPE</comment></event>
<event KT="Fact" id="E15">
<type class="Positive_regulation"/>
<theme idref="E12"/>
<cause idref="E17"/>
<clue>Tat also superactivates the HIV-1 promoter <linkCause>through</linkCause> a <corefCause>TAR-independent mechanism</corefCause>, including tumor necrosis factor alpha-induced and protein kinase C (PKC)-dependent activation of NF-kappa B, and inhibitors of Tat and NF-kappa B cooperatively down-regulate this Tat-mediated LTR superactivation.</clue>
<comment>NO CLUETYPE</comment></event>
<event KT="Other" Polarity="Negative" assertion="non-exist" id="E14">
<type class="Regulation"/>
<theme idref="E16"/>
<cause idref="T16"/>
<clue>Tat also superactivates the HIV-1 promoter through a TAR-<clueType><cluePolarity>independent</cluePolarity></clueType> mechanism, including tumor necrosis factor alpha-induced and protein kinase C (PKC)-dependent activation of NF-kappa B, and inhibitors of Tat and NF-kappa B cooperatively down-regulate this Tat-mediated LTR superactivation.</clue>
</event>
<event KT="Other" Polarity="Negative" assertion="non-exist" id="E42">
<type class="Regulation"/>
<theme idref="E17"/>
<cause idref="T16"/>
<clue>Tat also superactivates the HIV-1 promoter through a TAR-<clueType><cluePolarity>independent</cluePolarity></clueType> mechanism, including tumor necrosis factor alpha-induced and protein kinase C (PKC)-dependent activation of NF-kappa B, and inhibitors of Tat and NF-kappa B cooperatively down-regulate this Tat-mediated LTR superactivation.</clue>
</event>
<event KT="Other" id="E16">
<type class="Positive_regulation"/>
<theme idref="T19"/>
<cause idref="A10"/>
<clue>Tat also superactivates the HIV-1 promoter through a TAR-independent mechanism, including tumor necrosis factor alpha<linkCause>-induced</linkCause> and protein kinase C (PKC)-dependent <clueType>activation</clueType> <linkTheme>of</linkTheme> NF-kappa B, and inhibitors of Tat and NF-kappa B cooperatively down-regulate this Tat-mediated LTR superactivation.</clue>
</event>
<event KT="Other" id="E17">
<type class="Regulation"/>
<theme idref="T19"/>
<cause idref="T18"/>
<clue>Tat also superactivates the HIV-1 promoter through a TAR-independent mechanism, including tumor necrosis factor alpha-induced and protein kinase C (PKC)<linkCause>-dependent</linkCause> <clueType>activation</clueType> <linkTheme>of</linkTheme> NF-kappa B, and inhibitors of Tat and NF-kappa B cooperatively down-regulate this Tat-mediated LTR superactivation.</clue>
</event>
<event KT="Fact" id="E18">
<type class="Negative_regulation"/>
<theme idref="E13"/>
<cause idref="A11" idref1="T20"/>
<cause idref="A11" idref1="T21"/>
<clue>Tat also superactivates the HIV-1 promoter through a TAR-independent mechanism, including tumor necrosis factor alpha-induced and protein kinase C (PKC)-dependent activation of NF-kappa B, and inhibitors of Tat and NF-kappa B <clueType>cooperatively down-regulate</clueType> <corefTheme>this Tat-mediated LTR superactivation</corefTheme>.</clue>
</event>
<event KT="Fact" id="E19">
<type class="Negative_regulation"/>
<theme idref="E15"/>
<cause idref="A11" idref1="T20"/>
<cause idref="A11" idref1="T21"/>
<clue>Tat also superactivates the HIV-1 promoter through a TAR-independent mechanism, including tumor necrosis factor alpha-induced and protein kinase C (PKC)-dependent activation of NF-kappa B, and inhibitors of Tat and NF-kappa B <clueType>cooperatively down-regulate</clueType> <corefTheme>this Tat-mediated LTR superactivation</corefTheme>.</clue>
</event>
<event KT="Other" id="E20">
<type class="Positive_regulation"/>
<theme idref="T24"/>
<cause idref="T23"/>
<clue>Tat also superactivates the HIV-1 promoter through a TAR-independent mechanism, including tumor necrosis factor alpha-induced and protein kinase C (PKC)-dependent activation of NF-kappa B, and inhibitors of Tat and NF-kappa B cooperatively down-regulate this Tat-<linkCause>mediated</linkCause> LTR <clueType>superactivation</clueType>.</clue>
</event>
<sentence id="S4">In this study, a combined pharmacologic and genetic strategy using two <term id="T25" lex="PKC" sem="Protein_molecule">PKC</term> (<term id="T26" lex="NF-kappa_B" sem="Protein_complex">NF-kappa B</term>) inhibitors, <term id="T27" lex="pentoxifylline" sem="Organic_compound_other">pentoxifylline</term> (<term id="T28" lex="PTX" sem="Organic_compound_other">PTX</term>) and <term id="T29" lex="Go-6976" sem="Organic_compound_other">Go-6976</term>, and a stably expressed <term id="T30" lex="anti-Tat_single-chain_intracellular_antibody" sem="Protein_molecule">anti-<term id="T31" lex="Tat" sem="Protein_molecule">Tat</term> single-chain intracellular antibody</term> (<term id="T32" lex="sFv_intrabody" sem="Protein_molecule">sFv intrabody</term>) was employed to obtain cooperative inhibition of both <term id="A15" sem="DNA_domain_or_region"><term id="T33" lex="HIV-1" sem="Virus">HIV-1</term> <term id="T35" lex="LTR" sem="DNA_domain_or_region">LTR</term></term>-driven <term id="A12" sem="Other">gene expression</term> and <term id="T36" lex="HIV-1_replication" sem="Other"><term id="T37" lex="HIV-1" sem="Virus">HIV-1</term> replication</term>.</sentence>
<event id="E21" uncertainty="probable">
<type class="Negative_regulation"/>
<theme idref="E22"/>
<cause idref="T28"/>
<cause idref="E26"/>
<clue>In this study, a combined pharmacologic and genetic strategy using <corefCause>two PKC (NF-kappa B) inhibitors</corefCause>, pentoxifylline (PTX) and Go-6976, and a stably expressed anti-Tat single-chain intracellular antibody (sFv intrabody) was employed to obtain <clueType>cooperative inhibition</clueType> <linkTheme>of</linkTheme> both HIV-1 LTR-driven gene expression and HIV-1 replication.</clue>
</event>
<event id="E24" uncertainty="probable">
<type class="Negative_regulation"/>
<theme idref="E22"/>
<cause idref="T29"/>
<cause idref="E26"/>
<clue>In this study, a combined pharmacologic and genetic strategy using <corefCause>two PKC (NF-kappa B) inhibitors</corefCause>, pentoxifylline (PTX) and Go-6976, and a stably expressed anti-Tat single-chain intracellular antibody (sFv intrabody) was employed to obtain <clueType>cooperative inhibition</clueType> <linkTheme>of</linkTheme> both HIV-1 LTR-driven gene expression and HIV-1 replication.</clue>
</event>
<event id="E27" uncertainty="probable">
<type class="Negative_regulation"/>
<theme idref="E25"/>
<cause idref="T28"/>
<cause idref="E26"/>
<clue>In this study, a combined pharmacologic and genetic strategy using <corefCause>two PKC (NF-kappa B) inhibitors</corefCause>, pentoxifylline (PTX) and Go-6976, and a stably expressed anti-Tat single-chain intracellular antibody (sFv intrabody) was employed to obtain <clueType>cooperative inhibition</clueType> <linkTheme>of</linkTheme> both HIV-1 LTR-driven gene expression and HIV-1 replication.</clue>
</event>
<event id="E28" uncertainty="probable">
<type class="Negative_regulation"/>
<theme idref="E25"/>
<cause idref="T29"/>
<cause idref="E26"/>
<clue>In this study, a combined pharmacologic and genetic strategy using <corefCause>two PKC (NF-kappa B) inhibitors</corefCause>, pentoxifylline (PTX) and Go-6976, and a stably expressed anti-Tat single-chain intracellular antibody (sFv intrabody) was employed to obtain <clueType>cooperative inhibition</clueType> <linkTheme>of</linkTheme> both HIV-1 LTR-driven gene expression and HIV-1 replication.</clue>
</event>
<event KT="Other" id="E22">
<type class="Positive_regulation"/>
<theme idref="A12"/>
<cause idref="A15"/>
<clue>In this study, a combined pharmacologic and genetic strategy using two PKC (NF-kappa B) inhibitors, pentoxifylline (PTX) and Go-6976, and a stably expressed anti-Tat single-chain intracellular antibody (sFv intrabody) was employed to obtain cooperative inhibition of both HIV-1 LTR-<clueType>driven</clueType> gene expression and HIV-1 replication.</clue>
<comment>NER: T34 del &quot;LTR-driven gene expression&quot;</comment></event>
<event KT="Other" id="E25">
<type class="Viral_life_cycle"/>
<theme idref="T37"/>
<clue>In this study, a combined pharmacologic and genetic strategy using two PKC (NF-kappa B) inhibitors, pentoxifylline (PTX) and Go-6976, and a stably expressed anti-Tat single-chain intracellular antibody (sFv intrabody) was employed to obtain cooperative inhibition of both HIV-1 LTR-driven gene expression and HIV-1 <clueType>replication</clueType>.</clue>
</event>
<event id="E26">
<type class="Gene_expression"/>
<theme idref="T32"/>
<clue>In this study, a combined pharmacologic and genetic strategy using two PKC (NF-kappa B) inhibitors, pentoxifylline (PTX) and Go-6976, and a stably <clueType>expressed</clueType> anti-Tat single-chain intracellular antibody (sFv intrabody) was employed to obtain cooperative inhibition of both HIV-1 LTR-driven gene expression and HIV-1 replication.</clue>
</event>
<sentence id="S5">Treatment of cells with <term id="T38" lex="PTX" sem="Organic_compound_other">PTX</term> and <term id="T39" lex="Go-6976" sem="Organic_compound_other">Go-6976</term> resulted in cooperative inhibition of both <term id="T41" lex="HIV-1_LTR" sem="DNA_domain_or_region"><term id="T42" lex="HIV-1" sem="Virus">HIV-1</term> LTR</term>-driven <term id="A13" sem="Other">gene expression</term> and <term id="T43" lex="HIV-1_replication" sem="Other"><term id="T44" lex="HIV-1" sem="Virus">HIV-1</term> replication</term>.</sentence>
<event id="E29">
<type class="Negative_regulation"/>
<theme idref="E31"/>
<cause idref="T38"/>
<cause idref="T39"/>
<clue>Treatment of <clueLoc>cells</clueLoc> with PTX and Go-6976 <clueType>resulted in cooperative inhibition</clueType> <linkTheme>of</linkTheme> both HIV-1 LTR-driven gene expression and HIV-1 replication.</clue>
</event>
<event id="E30">
<type class="Negative_regulation"/>
<theme idref="E33"/>
<cause idref="T38"/>
<cause idref="T39"/>
<clue>Treatment of <clueLoc>cells</clueLoc> with PTX and Go-6976 <clueType>resulted in cooperative inhibition</clueType> <linkTheme>of</linkTheme> both HIV-1 LTR-driven gene expression and HIV-1 replication.</clue>
</event>
<event KT="Other" id="E31">
<type class="Positive_regulation"/>
<theme idref="A13"/>
<cause idref="T41"/>
<clue>Treatment of cells with PTX and Go-6976 resulted in cooperative inhibition of both HIV-1 LTR-<clueType>driven</clueType> gene expression and HIV-1 replication.</clue>
</event>
<event KT="Other" id="E33">
<type class="Viral_life_cycle"/>
<theme idref="T44"/>
<clue>Treatment of cells with PTX and Go-6976 resulted in cooperative inhibition of both HIV-1 LTR-driven gene expression and HIV-1 <clueType>replication</clueType>.</clue>
</event>
<sentence id="S6">In addition, the combined use of <term id="T45" lex="anti-Tat_sFv_intrabody" sem="Protein_family_or_group">anti-<term id="T46" lex="Tat" sem="Protein_molecule">Tat</term> sFv intrabodies</term> and the two <term id="T47" lex="NF-kappa_B_inhibitor" sem="Organic_compound_other"><term id="T48" lex="NF-kappa_B" sem="Protein_complex">NF-kappa B</term> inhibitors</term> retained the virus in the latent state for as long as 45 days.</sentence>
<event id="E34">
<type class="Negative_regulation"/>
<theme idref="T42"/>
<cause idref="T45"/>
<cause idref="T38"/>
<cause idref="T39"/>
<clue>In addition, the combined use of anti-Tat sFv intrabodies and the <corefCause>two NF-kappa B inhibitors</corefCause> <clueType>retained</clueType> <corefTheme>the virus</corefTheme> <clueType>in the latent state</clueType> <clueTime>for as long as 45 days</clueTime>.</clue>
<comment>CAUTION: three CAUSEs in combination</comment></event>
<sentence id="S7">The combined treatment resulted in more durable inhibition of <term id="T49" lex="HIV-1_replication" sem="Other"><term id="T50" lex="HIV-1" sem="Virus">HIV-1</term> replication</term> than was seen with the <term id="T51" lex="NF-kappa_B_inhibitor" sem="Organic_compound_other"><term id="T52" lex="NF-kappa_B" sem="Protein_complex">NF-kappa B</term> inhibitors</term> alone or the anti-<term id="T53" lex="Tat_sFv_intrabody" sem="Protein_family_or_group"><term id="T54" lex="Tat" sem="Protein_molecule">Tat</term> sFv intrabodies</term> alone.</sentence>
<event id="E35">
<type class="Negative_regulation"/>
<theme idref="E36"/>
<cause idref="T45"/>
<cause idref="T38"/>
<cause idref="T39"/>
<clue><corefCause>The combined treatment</corefCause> <clueType>resulted in</clueType> more durable <clueType>inhibition</clueType> <linkTheme>of</linkTheme> HIV-1 replication than was seen with the NF-kappa B inhibitors alone or the anti-Tat sFv intrabodies alone.</clue>
</event>
<event KT="Other" id="E36">
<type class="Viral_life_cycle"/>
<theme idref="T50"/>
<clue>The combined treatment resulted in more durable inhibition of HIV-1 <clueType>replication</clueType> than was seen with the NF-kappa B inhibitors alone or the anti-Tat sFv intrabodies alone.</clue>
</event>
<event id="E37">
<type class="Positive_regulation"/>
<theme idref="E36"/>
<cause idref="T51"/>
<clue>The combined treatment resulted in more durable inhibition of HIV-1 replication than was <clueKT>seen</clueKT> <linkCause>with</linkCause> the NF-kappa B inhibitors alone or the anti-Tat sFv intrabodies alone.</clue>
<comment>NO CLUETYPE</comment></event>
<event id="E38">
<type class="Positive_regulation"/>
<theme idref="E36"/>
<cause idref="T53"/>
<clue>The combined treatment resulted in more durable inhibition of HIV-1 replication than was <clueKT>seen</clueKT> <linkCause>with</linkCause> the NF-kappa B inhibitors alone or the anti-Tat sFv intrabodies alone.</clue>
<comment>NO CLUETYPE</comment></event>
<sentence id="S8">Together, these results suggest that in future clinical gene therapy trials, a combined pharmacologic and genetic strategy like the one reported here may improve the survival of <term id="T55" lex="transduced_cell" sem="Cell_cultured">transduced cells</term> and prolong clinical benefit.</sentence>
<event CL="L1" KT="Analysis" id="E39" uncertainty="probable">
<type class="Positive_regulation"/>
<theme idref="E41"/>
<cause idref="E35"/>
<clue>Together, these results <clueKT>suggest</clueKT> that in future clinical gene therapy trials, a combined pharmacologic and genetic strategy like <corefCause>the one</corefCause> reported here <clueCL>may</clueCL> <clueType>improve</clueType> the survival <linkTheme>of</linkTheme> transduced cells and prolong clinical benefit.</clue>
</event>
<event KT="Other" id="E41">
<type class="Physiological_process"/>
<theme idref="T55"/>
<clue>Together, these results suggest that in future clinical gene therapy trials, a combined pharmacologic and genetic strategy like the one reported here may improve the <clueType>survival</clueType> <linkTheme>of</linkTheme> transduced cells and prolong clinical benefit.</clue>
</event>
</AbstractText>
</Abstract></Article></MedlineCitation></PubmedArticle></PubmedArticleSet></Annotation>
